What We Do

Focusing on the CDMO business for new modalities in addition to new drug development

As a total healthcare company, the Fujifilm Group is engaged in a wide range of businesses in the three areas of “Prevention,” “Diagnosis,” and “Treatment.” As a core company in the “Treatment” area, FUJIFILM Toyama Chemical Co., Ltd (FFTC)., is engaged in the research, development, production, and sale of prescription pharmaceuticals.

Leveraging over 40 years of knowledge in the field of anti-infective drugs, the company has recently focused its efforts on the business of contract manufacturing as the only company who can manufacture sterile penicillin antibiotics products.

In addition, FFTC is driving its contract process development and manufacturing organization business (CDMO Business) for formulations using lipid nanoparticle (LNP), liposome, and other Drug Delivery System (DDS) technologies, which are also known in the mRNA vaccines for COVID-19. In 2020, the company began operations at a new production facility to handle commercial products. Going forward, it will enhance the CDMO Business, which also addresses new modalities including LNP to meet customer needs.

Main Business Fields

As part of its drug research and development efforts, FFTC primarily develops therapeutic drugs having unique mechanisms of action in the areas of Infectious Diseases and Central Nervous System Diseases, where significant unmet medical needs still exist, such as therapeutic drugs for diseases caused by highly virulent viruses with high fatality rates and a fundamental therapeutic agent for Alzheimer’s disease which stops its progression.

FFTC will deploy its One-Stop-Shop CDMO Business ranging from the design to process development and commercial production of formulations using LNP and liposome DDS technologies by leveraging the advanced nano dispersion, analysis, and synthesis technologies that Fujifilm has cultivated and evolved through the development of a wide range of products including photographic films, as well as the company’s production know-how and manufacturing facilities.

Toyama 701 Facility

FFTC undertakes contracts for manufacturing LNP and liposome formulations for clinical trials and commercial sales at its LNP/liposome production facility, the first of its kind in Japan, located in Toyama City.

FFTC also engages in contract manufacturing as the only manufacturer in Japan that synthesizes penicillin antibiotics and manufactures sterile products.

We offer products and services to meet the needs of on-site medical treatment such as drug dispensing auditing support systems “PROOFIT 1D (one dose)” that utilizes Fujifilm's image processing technology.